Excelsior Biopharma Inc. (TPEX:6496)

Taiwan · Delayed Price · Currency is TWD

24.90

+0.40 (1.63%)

Jun 18, 2026, 12:57 PM CST

-1.97% (1Y)

Market Cap	1.16B -6.0%
Revenue (ttm)	906.42M +2.8%
Net Income	-197.05M
EPS	-4.08
Shares Out	46.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,120
Open	24.95
Previous Close	24.50
Day's Range	24.90 - 24.95
52-Week Range	22.50 - 30.55
Beta	-0.15
Analysts	Hold
Price Target	57.00 (+128.92%)
Earnings Date	Aug 7, 2026

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmece... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1986

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6496

Full Company Profile

Financial Performance

In 2025, Excelsior Biopharma's revenue was 898.26 million, an increase of 4.22% compared to the previous year's 861.91 million. Losses were -183.17 million, 85.6% more than in 2024.

Financial Statements